Acquired Predisposing Conditions

Slide 1 · Acquired Predisposing Conditions

Chronic inflammation · Precursor lesions · Immunodeficiency

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Classify acquired states that increase susceptibility to neoplasia.

Connect chronic tissue injury with proliferation, DNA damage, and cell survival.

Distinguish hyperplasia, metaplasia, dysplasia, and carcinoma in situ.

Relate impaired T-cell immunity to virus-associated malignancies.

Use representative clinicopathologic associations without assuming inevitable progression.

Slide 3 · Predisposition modifies risk—not diagnosis

Predisposing condition

Increases susceptibility to malignancy

May act over a prolonged period

Can exist without cancer

Malignant neoplasm

A transformed clone has emerged

Requires additional biologic changes

Must be diagnosed on its own evidence

A risk state and an established cancer are not interchangeable diagnoses.

Slide 4 · Three acquired categories

Chronic inflammatory disorders

Persistent damage and repair

DNA-damaging reactive species

Growth and survival signals

Precursor lesions

Localized epithelial changes

Hyperplasia, metaplasia, dysplasia

Variable chance of progression

Immunodeficiency

Defective antiviral immune control

Especially T-cell deficiency

Virus-associated cancers prominent

Slide 5 · Different routes converge on neoplastic risk

Acquired risk state

Altered tissue or immune environment

Opportunity for transforming changes

Increased cancer susceptibility

Schematic — risk pathway

Inflammation and precursor lesions often increase epithelial replication.

Immunodeficiency predominantly alters control of infected or abnormal cells.

Slide 6 · Cell replication creates a susceptible field

Chronic injury / trophic stimulus

Repeated proliferative cycles

Somatic mutation opportunity

Selection of altered cell clones

Schematic — risk pathway

Proliferating cells as particularly vulnerable to oncogenic mutation.

Proliferation alone is not sufficient to diagnose transformation.

Slide 7 · A useful distinction: Field versus clone

At-risk field

Tissue-wide regenerative or precursor change

May be reversible or stable

Cannot be equated with invasive cancer

Tumor clone

An altered precursor cell expands

Later changes may generate malignancy

Morphologic assessment remains decisive

Slide 8 · Virchow’s inflammation–cancer connection

Rudolf Virchow proposed a link between chronic inflammation and cancer in 1863.

The association now extends across many infectious and noninfectious disorders.

Causal pathways differ among inflammatory conditions and tissues.

The association is clinically useful because some upstream causes are preventable.

Slide 9 · Inflammation has infectious and noninfectious causes

Infectious

H. Pylori gastritis

Chronic viral hepatitis

Schistosomal cystitis

Noninfectious

Inflammatory bowel disease

Chronic reflux injury

Autoimmune gland inflammation

Physical / irritant injury

Asbestos-related injury

Chronic gallstone-associated inflammation

Long-standing draining sinuses

Slide 10 · Persistent injury drives repeated repair

Tissue injury

Inflammation

Compensatory cell proliferation

Continued susceptibility

Schematic — risk pathway

The regenerative response is normally reparative.

Persistent insult creates repeated cycles of tissue damage and cell replacement.

Slide 11 · Proliferation is one mechanistic route

Regeneration expands the population of cycling cells after injury.

Repeated cell division increases opportunities for heritable somatic changes.

A proliferative environment is permissive—not itself proof of neoplasia.

Additional alterations are needed for malignant transformation.

Slide 12 · Inflammation may expand stem-cell pools

Sustained tissue damage

Increased regenerative demand

Larger tissue stem-cell pool

More susceptible target cells

Schematic — risk pathway

Stem-cell expansion as a possible mechanism in some settings.

This is a proposed contributor rather than a universal feature of all inflammation.

Slide 13 · Reactive oxygen species can damage DNA

Activated immune cells

Reactive oxygen species

DNA injury

Oncogenic alterations may accumulate

Schematic — risk pathway

Inflammatory oxidative injury acts alongside the proliferative response.

DNA damage does not mean that every affected cell becomes malignant.

Slide 14 · Inflammatory mediators may sustain damaged cells

Activated inflammatory cells

Pro-survival mediators

Persistence of genomically injured cells

Opportunity for clonal evolution

Schematic — risk pathway

Survival even in the presence of genomic damage.

This route complements rather than replaces mutation-generating mechanisms.

Slide 15 · Mechanisms act together, not in isolation

Proliferation

More rounds of replication

More opportunities for somatic change

Damage

Oxidative products injure DNA

Regeneration follows ongoing injury

Survival

Inflammatory signals prolong viability

Damaged cells may persist

Repeated injury, mutation opportunity, and survival signals can reinforce one another.

Slide 16 · Which tumor classes arise in inflamed tissues?

Most frequent pattern

Carcinomas are prominent

Frequently arise in chronically injured epithelia

Important exceptions

Mesothelioma is included

Several lymphomas occur in inflammatory settings

An inflammation-related neoplasm need not be a carcinoma.

Slide 17 · Chronic inflammatory associations: Digestive tract

Inflammatory condition

Associated neoplasm

Inflammatory bowel disease

Colorectal carcinoma

Reflux esophagitis / Barrett esophagus

Esophageal carcinoma

Chronic cholecystitis

Gallbladder carcinoma

Pancreatitis

Pancreatic carcinoma

Associations identify risk contexts; They do not establish that every case progresses.

Slide 18 · Chronic inflammatory associations: Infection

Chronic condition / agent

Associated neoplasm

H. pylori gastritis / ulcers

Gastric adenocarcinoma; gastric MALT lymphoma

Hepatitis B or C infection

Hepatocellular carcinoma

Schistosomiasis-associated cystitis

Bladder carcinoma

Opisthorchis-associated cholangitis

Cholangiocarcinoma

Infectious causes can act through different combinations of inflammation and pathogen-specific effects.

Slide 19 · Chronic inflammatory associations: Other sites

Condition

Associated malignancy

Lichen sclerosus

Vulvar squamous cell carcinoma

Sjögren syndrome; Hashimoto thyroiditis

Extranodal marginal zone (MALT) lymphoma

Long-standing osteomyelitis / draining sinus

Carcinoma in draining sinus

Asbestos-related / silicosis-associated injury

Lung carcinoma; mesothelioma linked to asbestos

The type of at-risk tissue helps determine the expected tumor phenotype.

Slide 20 · H. Pylori: Sustained gastric injury

Helicobacter pylori infection

Chronic gastritis

Persistent mucosal injury / proliferation

Gastric cancer susceptibility

Schematic — risk pathway

Chronic infection to gastric carcinoma and gastric MALT lymphoma.

The presence of infection does not itself establish a neoplastic diagnosis.

Slide 21 · H. Pylori has two key neoplastic associations

Gastric adenocarcinoma

Epithelial malignancy

Associated with chronic gastritis

Gastric MALT lymphoma

Lymphoid malignancy

Also associated with persistent H. Pylori gastritis

One inflammatory setting may be linked to different tumor lineages.

Slide 22 · Removing H. Pylori targets an upstream risk state

Identify H. Pylori gastritis

Effective antibiotic therapy

Resolution of chronic inflammatory driver

Reduced carcinogenic opportunity

Schematic — risk pathway

The textbook uses eradication as a prevention example.

Treatment of inflammation is not treatment of an already established malignancy.

Slide 23 · Chronic viral hepatitis predisposes to liver cancer

Hepatitis B / C

Chronic hepatic inflammation

Ongoing tissue injury and repair

Hepatocellular carcinoma risk

Schematic — risk pathway

The source table links chronic hepatitis with hepatocellular carcinoma.

Other pathogen-specific pathways are outside the source excerpt’s scope.

Slide 24 · Hepatitis B vaccination is cancer prevention

Hepatitis B immunization

Reduced HBV infection burden

Less HBV-linked chronic liver disease

Lower hepatocellular carcinoma incidence

Schematic — risk pathway

Robbins explicitly reports a significant decrease in hepatocellular carcinoma following HBV vaccination.

Preventing the causative infection interrupts an upstream carcinogenic route.

Slide 25 · Inflammatory bowel disease and colorectal cancer

Inflammatory bowel disease is associated with colorectal carcinoma.

The relevant pathology is persistent intestinal mucosal inflammation.

Repeated epithelial injury and regeneration help explain the association.

A cancer-risk association does not imply that every patient develops carcinoma.

Slide 26 · Reflux injury and Barrett esophagus

Acid-mediated esophageal injury

Replacement of squamous epithelium

Barrett metaplastic epithelium

Increased risk of esophageal carcinoma

Schematic — risk pathway

Barrett esophagus illustrates an overlap between inflammation and a precursor lesion.

The metaplastic change is adaptive but occurs within an at-risk clinical setting.

Slide 27 · Barrett change is an epithelial substitution

Schematic — not a histologic specimen

Before

Stratified squamous lining

After

Glandular-type lining

Esophageal stratified squamous cells are replaced by glandular epithelium.

The new lining is better suited to chronic acid exposure.

Metaplasia itself does not prove dysplasia.

Slide 28 · Autoimmune inflammation may precede lymphoma

Sjögren syndrome

Chronic autoimmune salivary-gland inflammation

Associated extranodal marginal zone lymphoma

Hashimoto thyroiditis

Chronic autoimmune thyroid inflammation

Associated extranodal marginal zone lymphoma

The MALT lymphoma association is different from the epithelial carcinoma pattern.

Slide 29 · Pancreas and gallbladder: Persistent injury

Pancreatitis

Chronic pancreatic inflammatory disease

Associated pancreatic carcinoma

Chronic cholecystitis

Persistent gallbladder inflammation

Associated gallbladder carcinoma

The two organs illustrate inflammation-associated epithelial malignancy.

Slide 30 · Chronic vulvar and draining-sinus disease

Lichen sclerosus

Chronic inflammatory vulvar dermatosis

Associated vulvar squamous carcinoma

Chronic osteomyelitis

Long-standing draining sinus tract

Carcinoma may arise in the draining tract

Site-specific chronic injury can create a local cancer-predisposing environment.

Slide 31 · Parasitic infection and urinary tract cancer

Schistosomiasis

Chronic cystitis

Persistent bladder injury

Bladder carcinoma association

Schematic — risk pathway

The source classifies this as a chronic inflammatory state associated with cancer.

The table does not specify histologic subtype; Avoid assuming one here.

Slide 32 · Liver flukes and biliary tract malignancy

Opisthorchis viverrini infection

Chronic cholangitis

Sustained biliary injury

Cholangiocarcinoma association

Schematic — risk pathway

The relevant at-risk epithelium is the biliary lining.

The source table links liver fluke–associated cholangitis to cholangiocarcinoma.

Slide 33 · Mineral particles: Distinguish associations

Asbestos exposure

Associated lung carcinoma

Strong association with mesothelioma

Silica-associated injury

Silicosis linked to chronic lung injury

Table groups silicosis with lung malignancy

Do not infer that silica causes mesothelioma simply because a printed table groups particle injuries.

Slide 34 · Inflammation-related associations are heterogeneous

Epithelial sites

Colon, stomach, esophagus

Liver, pancreas, gallbladder

Vulva and bladder

Lymphoid sites

Gastric MALT lymphoma

Autoimmune-associated MALT lymphoma

Other tumor tissue

Mesothelioma in asbestos-associated settings

Carcinoma from chronic draining sinus

Slide 35 · Interpret inflammatory associations carefully

An epidemiologic association is not a diagnosis of neoplasia.

Not every implicated exposure acts through inflammation alone.

Underlying infections, repair, immune responses, and direct carcinogenic effects may coexist.

Use source-specific rather than universal causal language.

Slide 36 · What defines a precursor lesion?

Localized morphologic change identifies an epithelial field at increased risk.

Hyperplasia, metaplasia, and dysplasia among the patterns.

Some precursor lesions are benign neoplasms with nontrivial progression risk.

A precursor designation is distinct from a diagnosis of invasive malignancy.

Slide 37 · Hyperplasia, metaplasia, and dysplasia

Change

Core morphologic idea

Interpretation

Hyperplasia

Increase in epithelial cell number

May reflect persistent trophic drive

Metaplasia

One mature cell type replaced by another

Adaptation to chronic injury

Dysplasia

Atypical cells and disordered architecture

Premalignant change

These are different tissue responses—not interchangeable diagnostic terms.

Slide 38 · An at-risk field is defined morphologically

Schematic — not a histologic specimen

Before

Reference epithelium

After

Expanded epithelial field

The precursor change can involve a localized sheet of epithelium.

Microscopic assessment identifies the change and its distribution.

The field may persist without developing invasive carcinoma.

Slide 39 · Hyperplasia may follow sustained trophic stimulation

Persistent trophic signal

Increased cell proliferation

Hyperplastic epithelium

Potential precursor context

Schematic — risk pathway

The source highlights prolonged growth stimulation as one cause of hyperplastic precursors.

“Hyperplasia” by itself does not mean a premalignant lesion at every anatomic site.

Slide 40 · Endometrial hyperplasia illustrates hormonal drive

Sustained estrogenic stimulation

Endometrial cell proliferation

Endometrial hyperplasia

Cancer-predisposing precursor context

Schematic — risk pathway

This as a common hyperplastic precursor example.

The source excerpt does not provide a histologic subclassification or numerical progression rates.

Slide 41 · Metaplasia is an adaptive substitution

A differentiated epithelial cell type is replaced by another type.

This generally occurs with ongoing damage, repair, and regeneration.

The replacement lining can better withstand the chronic insult.

Adaptation does not automatically imply dysplasia or carcinoma.

Slide 42 · Barrett esophagus connects adaptation and risk

Chronic gastroesophageal reflux

Squamous epithelial injury

Glandular metaplastic lining

Epithelial precursor field

Schematic — risk pathway

Glandular replacement of the normal squamous lining.

Barrett esophagus is listed with reflux esophagitis among cancer-associated conditions.

Slide 43 · Bronchial squamous metaplasia: A second example

Schematic — not a histologic specimen

Before

Bronchial glandular-type lining

After

Squamous metaplasia

Chronic tobacco smoke irritates bronchial glandular epithelium.

The injured lining can be replaced by squamous epithelium.

Morphologic adaptation need not be dysplastic.

Slide 44 · Metaplasia and dysplasia must not be conflated

Metaplasia

Changed epithelial differentiation

Often adaptive to injury

May lack cytologic atypia

Dysplasia

Loss of orderly maturation

Nuclear atypia and disorganization

Premalignant morphologic pattern

Not all metaplastic epithelium is dysplastic.

Slide 45 · Dysplasia: Cellular atypia

Cellular pleomorphism is common.

Nuclei may be enlarged and hyperchromatic.

The nuclear-to-cytoplasmic ratio is increased.

Mitotic activity may be greater than in normal epithelium.

Slide 46 · Dysplasia: Disruption of tissue architecture

Orderly maturation from basal to superficial epithelial layers is impaired.

Basal-like atypical cells may extend toward the epithelial surface.

Mitotic figures may occur outside the usual basal proliferative compartment.

Cytologic changes should be integrated with architecture.

Slide 47 · Normal maturation versus epithelial dysplasia

Schematic — not a histologic specimen

Normal maturation

Basement membrane intact

Epithelial dysplasia

Basement membrane intact

Normal squamous epithelium matures from basal cells toward the surface.

Dysplasia loses this orderly gradient.

Basement membrane integrity separates intraepithelial atypia from invasion.

Slide 48 · Carcinoma in situ has an intact basement membrane

Schematic — not a histologic specimen

Normal maturation

Basement membrane intact

Carcinoma in situ

Basement membrane intact

Severe dysplasia involves the full thickness of the epithelium.

Atypical cells remain above an intact basement membrane.

Stromal invasion is absent by definition.

Slide 49 · Morphologic progression is not inevitable

Chronic injury / precursor field

Metaplasia or dysplasia

Possible additional alterations

Invasive carcinoma in a subset

Schematic — risk pathway

Dysplasia can precede invasive cancer, but progression is not assured.

Some dysplastic changes regress after removal of inciting causes.

Slide 50 · Dysplasia may regress after removing the cause

Possible regression

Elimination of inciting injury

Restoration of more normal architecture

Moderately severe dysplasia may reverse

Possible persistence / progression

Abnormal clone may persist

Additional changes can accumulate

Carcinoma in situ may remain noninvasive for years

Natural history depends on context; A single observation cannot predict every outcome.

Slide 51 · Benign neoplasms are not uniformly precancerous

Some benign tumors are clinically important cancer precursors.

Most benign tumors undergo malignant transformation rarely.

Some, such as lipomas, are not described as transforming into malignancy.

Risk depends on the specific lesion, not just the word “benign.”

Slide 52 · Colonic villous adenoma: A recognized precursor

Benign epithelial adenoma

Persistent adenomatous lesion

Additional neoplastic changes

Possible colorectal carcinoma

Schematic — risk pathway

The colonic villous adenoma as a classic precursor.

Adenoma is a neoplasm; It is not synonymous with invasive carcinoma.

Slide 53 · The textbook’s villous-adenoma risk estimate

About 50% of untreated colonic villous adenomas progress to cancer.

The statement is specific to the example and its untreated context.

Do not apply the percentage to all adenomas or all benign neoplasms.

The source excerpt gives no follow-up duration or risk stratification.

Slide 54 · Low transformation risk: Contrasting tumors

Benign lesion

How Robbins characterizes transformation

Colonic villous adenoma

Substantial risk if untreated (specific example)

Uterine leiomyoma

Malignant transformation rare

Pleomorphic adenoma

Malignant transformation rare

Lipoma

No malignant transformation described

“Benign” alone is inadequate to estimate future malignant potential.

Slide 55 · Why do most benign tumors remain benign?

Benign tumor

Relatively stable genome (hypothesis)

Few cancer-enabling changes

Minimal transformation risk

Schematic — risk pathway

Robbins explicitly calls the explanation unresolved.

Lack of genomic instability is offered as a possibility—not an established universal rule.

Slide 56 · Precursor lesion versus established malignancy

Feature

Precursor field / lesion

Invasive carcinoma

Morphology

Hyperplasia, metaplasia, dysplasia or selected adenoma

Invasive malignant neoplasm

Basement membrane

Not invaded by a precursor in situ process

May be penetrated in invasive carcinoma

Outcome

Progression may not occur

Cancer is already present

Risk assessment and detection of an invasive tumor answer different clinical questions.

Slide 57 · Immunodeficiency is a distinct risk mechanism

Cancer risk is increased in immunodeficient patients.

Deficient T-cell immunity is particularly implicated.

Weak immune responses may fail to eliminate virus-infected cells.

Immunodeficiency predisposes especially to oncogenic-virus-related tumors.

Slide 58 · T-cell surveillance limits virus-infected cells

Oncogenic-virus-infected cells

Functional T-cell response

Recognition / elimination

Reduced persistence of infected cells

Schematic — risk pathway

The protective mechanism is expressed in the source as a presumed explanation.

Failure of this control makes virus-associated neoplasms more likely.

Slide 59 · What changes when immune control is lost?

T-cell deficiency

Weaker infected-cell clearance

Persistence of infected populations

Greater cancer susceptibility

Schematic — risk pathway

The pathway concerns host surveillance rather than only epithelial proliferation.

Exact viruses and named tumor subtypes are discussed elsewhere.

Slide 60 · Cancer phenotypes in immunodeficiency

Lymphomas

Prominent virus-associated tumor category

Can arise during weakened immune surveillance

Carcinomas

Some carcinomas become more frequent

Risk depends on oncogenic context

Sarcomas / proliferations

Some sarcomas and sarcoma-like lesions

Not all are epithelial tumors

Slide 61 · Inflammation and immunodeficiency act differently

Mechanism

Inflammatory state

Immunodeficiency

Primary setting

Repeated injury and repair

Reduced antiviral immune control

Cellular emphasis

Proliferating injured tissue

Persisting virus-infected cells

Characteristic outcome

Many carcinomas; some lymphomas

Virus-linked tumors, especially lymphomas

Both increase susceptibility, but they should not be taught as one identical pathway.

Slide 62 · Application: Immune-suppressed host

Teaching vignette — hypothetical

A patient with marked T-cell immune dysfunction develops a new lymphoid mass. No diagnosis has yet been established.

Which acquired cancer-predisposing mechanism best explains the increased concern?

Interpretation

Impaired control of oncogenic-virus-infected cells; A lymphoma is a relevant tumor category. Tissue diagnosis remains necessary.

Slide 63 · Acquired and inherited susceptibility interact

Acquired background

Inflammation and exposures

Infectious or chemical effects

Inherited background

Germline susceptibility variants

May modify response to exposure

Observed cancer risk

Reflects both classes of influence

Often cannot be neatly partitioned

Slide 64 · A negative family history does not exclude heredity

Most cancers are sporadic rather than familial.

Absence of a family history does not exclude inherited contributions.

Germline susceptibility and acquired risk conditions can coexist.

Complex traits are difficult to allocate to one causal category.

Slide 65 · Genetic context changes exposure-related risk

Germline enzyme variation

Modified carcinogen metabolism

Different effect of the same exposure

Altered cancer susceptibility

Schematic — risk pathway

Cytochrome P-450 variation as an example.

A P-450 variant is discussed in relation to smoking-induced lung cancer.

Slide 66 · BRCA susceptibility also depends on context

Inherited BRCA1/BRCA2 alterations convey an important genetic susceptibility.

Historical birth-cohort differences in breast cancer risk among carriers.

Changing reproductive histories are suggested as one explanation.

This illustrates environmental modification of inherited risk rather than a universal numerical estimate.

Slide 67 · Risk assessment should identify the pathway

History / lesion

Predisposing pathway

Illustrative cancer concern

Chronic H. pylori gastritis

Infectious chronic inflammation

Gastric carcinoma / MALT lymphoma

Barrett metaplasia

Inflammation and epithelial precursor field

Esophageal carcinoma

Endometrial hyperplasia

Sustained trophic stimulation

Endometrial neoplasia risk

T-cell deficiency

Reduced immune surveillance

Virus-related tumors

The mechanism, tissue, and morphology should be specified—not simply “high cancer risk.”

Slide 68 · Prevention targets an upstream risk mechanism

Treat infection

H. Pylori antibiotic eradication

Removes persistent gastric inflammatory stimulus

Prevent infection

Hepatitis B vaccination

Reduces downstream hepatocellular carcinoma

Remove injury

End inciting source where feasible

Some dysplastic changes may regress

Slide 69 · Application: Two pathways in one patient

Teaching vignette — hypothetical

A patient with chronic gastroesophageal reflux develops a glandular lining in the distal esophagus; No atypia is identified.

What is the morphologic response, and why does the setting matter?

Interpretation

Barrett-type metaplasia: An adaptive epithelial substitution within an inflammation-associated cancer-risk setting; Dysplasia cannot be assumed.

Slide 70 · Application: Precursor ≠ carcinoma

Teaching vignette — hypothetical

A colonic biopsy contains adenomatous epithelium, with no evidence of stromal invasion in the submitted sample.

Does the lesion represent cancer, a precursor, or neither?

Interpretation

A benign epithelial neoplasm that can serve as a cancer precursor. The biopsy does not establish invasive carcinoma.

Slide 71 · Integrating the three major mechanisms

Chronic inflammation

Repeated tissue repair

ROS-related DNA injury

Pro-survival signaling

Precursor lesions

Recognizable epithelial fields

Variable natural history

Some reversible changes

Immunodeficiency

Impaired T-cell surveillance

Virus-infected cells may persist

Lymphomas and other cancers

Slide 72 · Five distinctions to retain

Increased cancer risk is not equivalent to cancer.

Inflammation may act through regeneration, DNA injury, and cell survival.

Metaplasia is not the same lesion as dysplasia.

An intact basement membrane excludes invasion in carcinoma in situ.

Immune deficiency promotes malignancy through deficient host surveillance.

Slide 73 · Primary reference

Primary source

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition.

Neoplasia: acquired predisposing conditions; precursor-lesion morphology; cancer epidemiology.